Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires

European Journal of Immunology

Volumn 41, Issue 11, 2011, Pages 3114-3124

  Oliveira, Cláudia C ^a,b   Querido, Bianca ^a   Sluijter, Marjolein ^a   Derbinski, Jens ^c   Van der Burg, Sjoerd H ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antigen processing; Cytotoxic T lymphocytes; Transporter associated with peptide processing

Indexed keywords

CARRIER PROTEIN; CERAMIDE SYNTHASE TRH4; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE TRANSPORTER TAP; SYNTHETASE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOPLASMIC RETICULUM; EPITHELIUM CELL; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; SPLEEN CELL; THYMOCYTE; WILD TYPE;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL SEPARATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80054894761     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141836     Document Type: Article

References (61)

1. Rock, K. L., Farfan-Arribas, D. J. and Shen, L., Proteases in MHC class I presentation and cross-presentation. J. Immunol. 2010. 184: 9-15.
2. Yewdell, J. W., Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 2007. 19: 79-86.
3. Wearsch, P. A. and Cresswell, P., The quality control of MHC class I peptide loading. Curr. Opin. Cell Biol. 2008. 20: 624-631.
4. Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R. and Wearsch, P. A., Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 2005. 207: 145-157.
5. Jensen, P. E., Recent advances in antigen processing and presentation. Nat. Immunol. 2007. 8: 1041-1048.
6. Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W., Eichmann, K. and Niedermann, G., A giant protease with potential to substitute for some functions of the proteasome. Science 1999. 283: 978-981.
7. Glas, R., Bogyo, M., McMaster, J. S., Gaczynska, M. and Ploegh, H. L., A proteolytic system that compensates for loss of proteasome function. Nature 1998. 392: 618-622.
8. Kessler, J. H., Khan, S., Seifert, U., Le Gall, S., Chow, K. M., Paschen, A., Bres-Vloemans, S. A. et al., Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat. Immunol. 2011. 12: 45-53.
9. Parmentier, N., Stroobant, V., Colau, D., de Diesbach, P., Morel, S., Chapiro, J., van Endert, P. and Van den Eynde, B. J., Production of an antigenic peptide by insulin-degrading enzyme. Nat. Immunol. 2010. 11: 449-454.
10. Seifert, U., Maranon, C., Shmueli, A., Desoutter, J. F., Wesoloski, L., Janek, K., Henklein, P. et al., An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 2003. 4: 375-379.
11. Hammer, G. E., Kanaseki, T. and Shastri, N., The final touches make perfect the peptide-MHC class I repertoire. Immunity 2007. 26: 397-406.
12. Peaper, D. R. and Cresswell, P., Regulation of MHC class I assembly and peptide binding. Annu. Rev. Cell Dev. Biol. 2008. 24: 343-368.
13. Scholz, C. and Tampe, R., The peptide-loading complex-antigen translocation and MHC class I loading. Biol. Chem. 2009. 390: 783-794.
14. Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L. and Tonegawa, S., TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+T cells. Cell 1992. 71: 1205-1214.
15. Griffin, B. D., Verweij, M. C. and Wiertz, E. J., Herpesviruses and immunity: the art of evasion. Vet. Microbiol. 2010. 143: 89-100.
16. Hansen, T. H. and Bouvier, M., MHC class I antigen presentation: learning from viral evasion strategies. Nat. Rev. Immunol. 2009. 9: 503-513.
17. Campoli, M. and Ferrone, S., HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008. 27: 5869-5885.
18. Carretero, R., Cabrera, T., Gil, H., Saenz-Lopez, P., Maleno, I., Aptsiauri, N., Cozar, J. M. and Garrido, F., BCG immunotherapy of bladder cancer induces selection of HLA class I-deficient tumor cells. Int. J. Cancer 2010. 129: 839-846.
19. Seliger, B., Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 2008. 57: 1719-1726.
20. +T cell repertoire that displays both diversity and peptide specificity. Eur. J. Immunol. 1996. 26: 288-293.
21. Cerundolo, V. and de la Salle, H., Description of HLA class I- and CD8-deficient patients: insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin. Immunol. 2006. 18: 330-336.
22. de la Salle, H., Houssaint, E., Peyrat, M. A., Arnold, D., Salamero, J., Pinczon, D., Stevanovic, S. et al., Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. J. Immunol. 1997. 158: 4555-4563.
23. Gadola, S. D., Moins-Teisserenc, H. T., Trowsdale, J., Gross, W. L. and Cerundolo, V., TAP deficiency syndrome. Clin. Exp. Immunol. 2000. 121: 173-178.
24. Moins-Teisserenc, H. T., Gadola, S. D., Cella, M., Dunbar, P. R., Exley, A., Blake, N., Baykal, C. et al., Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999. 354: 1598-1603.
25. Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F. and Engelhard, V. H., HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992. 255: 1264-1266.
26. Wei, M. L. and Cresswell, P., HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992. 356: 443-446.
27. Weinzierl, A. O., Rudolf, D., Hillen, N., Tenzer, S., van Endert, P., Schild, H., Rammensee, H. G. and Stevanovic, S., Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 2008. 38: 1503-1510.
28. Lemberg, M. K. and Martoglio, B., Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol. Cell 2002. 10: 735-744.
29. Martoglio, B. and Dobberstein, B., Signal sequences: more than just greasy peptides. Trends Cell Biol. 1998. 8: 410-415.
30. Gil-Torregrosa, B. C., Raul, C. A. and Del Val, M., Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J. Exp. Med. 1998. 188: 1105-1116.
31. Leonhardt, R. M., Fiegl, D., Rufer, E., Karger, A., Bettin, B. and Knittler, M. R., Post-endoplasmic reticulum rescue of unstable MHC class I requires proprotein convertase PC7. J. Immunol. 2010. 184: 2985-2998.
32. -/- CD8+T lymphocytes in vivo. J. Immunol. 2009. 183: 4639-4647.
33. Thomas, G., Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002. 3: 753-766.
34. Levy, M. and Futerman, A. H., Mammalian ceramide synthases. IUBMB Life 2010. 62: 347-356.
35. Riebeling, C., Allegood, J. C., Wang, E., MerrillJr, A. H. and Futerman, A. H., Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 2003. 278: 43452-43459.
36. van Hall, T., Wolpert, E. Z., van Veelen, P., Laban, S., van der Veer, M., Roseboom, M., Bres, S. et al., Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 2006. 12: 417-424.
37. Aladin, F., Lautscham, G., Humphries, E., Coulson, J. and Blake, N., Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER. Cancer Immunol. Immunother. 2007. 56: 1143-1152.
38. Snyder, H. L., Bacik, I., Bennink, J. R., Kearns, G., Behrens, T. W., Bachi, T., Orlowski, M. and Yewdell, J. W., Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing. J. Exp. Med. 1997. 186: 1087-1098.
39. Snyder, H. L., Bacik, I., Yewdell, J. W., Behrens, T. W. and Bennink, J. R., Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur. J. Immunol. 1998. 28: 1339-1346.
40. Verweij, M. C., Ressing, M. E., Knetsch, W., Quinten, E., Halenius, A., van Bel, N. et al., Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol. Immunol. 2011. 48: 835-845.
41. Chambers, B., Grufman, P., Fredriksson, V., Andersson, K., Roseboom, M., Laban, S., Camps, M. et al., Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res. 2007. 67: 8450-8455.
42. Klein, L., Hinterberger, M., Wirnsberger, G. and Kyewski, B., Antigen presentation in the thymus for positive selection and central tolerance induction. Nat. Rev. Immunol. 2009. 9: 833-844.
43. Momburg, F. and Tan, P., Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol. Immunol. 2002. 39: 217-233.
44. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M. and Melief, C. J., Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 1996. 156: 3308-3314.
45. van Hall, T., Sijts, A., Camps, M., Offringa, R., Melief, C., Kloetzel, P. M. and Ossendorp, F., Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 2000. 192: 483-494.
46. Shastri, N., Cardinaud, S., Schwab, S. R., Serwold, T. and Kunisawa, J., All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol. Rev. 2005. 207: 31-41.
47. Vyas, J. M., Van der Veen, A. G. and Ploegh, H. L., The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008. 8: 607-618.
48. Yewdell, J. W., Reits, E. and Neefjes, J., Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 2003. 3: 952-961.
49. Oliveira, C. C., van Veelen, P. A., Querido, B., de Ru, A., Sluijter, M., Laban, S., Drijfhout, J. W. et al., The nonpolymorphic MHC Qa-1b mediates CD8+T cell surveillance of antigen-processing defects. J. Exp. Med. 2010. 207: 207-221.
50. van Hall, T., Laban, S., Koppers-Lalic, D., Koch, J., Precup, C., Asmawidjaja, P., Offringa, R. and Wiertz, E. J., The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J. Immunol. 2007. 178: 657-662.
51. van Hall, T., Oliveira, C. C., Joosten, S. A. and Ottenhoff, T. H., The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect. 2010. 12: 910-918.
52. Lampen, M. H., Verweij, M. C., Querido, B., van der Burg, S. H., Wiertz, E. J. and van Hall, T., CD8+T cell responses against TAP-inhibited cells are readily detected in the human population. J. Immunol. 2010. 185: 6508-6517.
53. Lampen, M. H. and van Hall, T., Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 2011. 23: 293-298.
54. Durgeau, A., El Hage, F., Vergnon, I., Validire, P., de Montpréville, V., Besse, B., Soria, J.-C. et al., Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J. Immunol. 2011. In press.
55. El Hage, F., Stroobant, V., Vergnon, I., Baurain, J. F., Echchakir, H., Lazar, V., Chouaib, S. et al., Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc. Natl. Acad. Sci. USA 2008. 105: 10119-10124.
56. Chang, C. C., Campoli, M. and Ferrone, S., HLA class I defects in malignant lesions: what have we learned? Keio J. Med. 2003. 52: 220-229.
57. Hicklin, D. J., Marincola, F. M. and Ferrone, S., HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 1999. 5: 178-186.
58. van Hall, T., van Bergen, J., van Veelen, P. A., Kraakman, M., Heukamp, L. C., Koning, F., Melief, C. J. et al., Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J. Immunol. 2000. 165: 869-877.
59. Derbinski, J., Gabler, J., Brors, B., Tierling, S., Jonnakuty, S., Hergenhahn, M., Peltonen, L. et al., Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J. Exp. Med. 2005. 202: 33-45.
60. van Stipdonk, M. J., Badia-Martinez, D., Sluijter, M., Offringa, R., van Hall, T. and Achour, A., Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 2009. 69: 7784-7792.
61. Fletcher, A. L., Lukacs-Kornek, V., Reynoso, E. D., Pinner, S. E., Bellemare-Pelletier, A., Curry, M. S., Collier, A. R. et al., Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J. Exp. Med. 2010. 207: 689-697.